Aurora Cannabis (TSX:ACB) Stock: More Pain Ahead

Aurora Cannabis (TSX:ACB)(NYSE:ACB) is taking steps to shore up the balance sheet. Unfortunately, this will result in short-term pain for shareholders.

| More on:
cup of cappuccino with a sad face

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Speculative: it is a word that I have used to describe the cannabis sector since it first started making waves a few years ago. This week, Aurora Cannabis (TSX:ACB)(NYSE:ACB) announced a reverse stock split. This is yet another sign that the industry is struggling to gain a footing. 

Pot stocks took the world by storm in late 2017, when it was clear the Federal government was going to legalize recreational marijuana. The TSX was littered with new entrants on the promise of significant demand. This led to rich valuations, as retail investors looked to get rich quick. 

Unfortunately, the inevitable happened and in 2019, the industry came crashing down. The cannabis industry is in a year-long bear market with little to no signs of a rebound. Over this period, the Canadian Marijuana Index has lost 81.3% of its value. Ouch. 

For its part, industry-leading producer Aurora Cannabis is down 91.21% over the past year. At these levels, there are many investors in the red. Don’t blame COVID-19 either; this is a trend that started well before the virus attacked. 

Lack of trust

Since the start of 2019, we’ve seen several high-profile events. From the ouster of CEOs to illegal activity and everything in between, you’d be hard pressed to find any bit of good news. In late December, Aurora Cannabis forced out then Chief Operating Officer Cam Battley. In February, Chief Executive Officer Terry Booth also stepped down. 

Not surprisingly, there is now a significant lack of trust in industry leaders. Demand is less than forecasted, operational issues persist, and COVID-19 has simply exasperated all the previous issues. 

In only a couple of short years since legalization, supply is already outstripping demand. Companies are shelving further expansion, and it has now become a fight for survival. Now, not even industry leaders such as Aurora Cannabis can find the liquidity necessary to maintain operations and expand.

Aurora Cannabis takes new steps

At one point, cannabis companies had nearly unlimited access to capital from lenders. Companies such as Aurora Cannabis frequently used their highly valued stock as a means to make acquisitions. Over the past year, M&A is all but non-existent. 

Likewise, now that lending is drying up, there is only one way to mitigate issues and strengthen the balance sheet — equity raises. Pot stocks are tapping the equity markets at an unprecedented pace. Aurora is next in line. 

Aurora Cannabis intends to file a new prospectus supplement for a secondary offering to raise additional equity capital. When used to fund growth, share issues can be a good thing. In this case, however, further shareholder dilution is simply a means to keep the company afloat.

Along with this, the company will “consolidate all of its outstanding common shares on the basis of one common share for every 12 common shares currently outstanding.” In effect, this reverse stock split is a desperate attempt to increase its share price. Why now? 

The company’s share price is dropping to a point where it needs “to restore compliance with the NYSE’s continued listing standards.” That’s right, without such a move, the company is at risk of being delisted from the NYSE. 

This is how bad things are in the industry. 

Despite the allure of low share prices, my thoughts on the industry haven’t changed. It remains speculative at best. There are better places for investors to park their cash, as there is more pain ahead for Aurora Cannabis.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Mat Litalien has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »